CL 82198 Hydrochloride: Researcher Protocol & Usage Guide

CL 82198 hydrochloride is a selective, non-hydroxamate inhibitor of matrix metalloproteinase-13 (MMP-13, collagenase-3) widely used in research to probe cartilage degradation, osteoarthritis mechanisms, and related extracellular matrix remodeling pathways.

Target

MMP-13 (collagenase-3)

Inhibitor Class

Selective, non-hydroxamate MMP-13 inhibitor

SKU

C287353

Recommended Solvent

DMSO or aqueous buffer (see preparation section)

Storage Condition

Store at -20 °C, protect from light and moisture

Application

MMP-13 activity assays, osteoarthritis research, ECM remodeling studies

Background and Mechanism of Action

CL 82198 hydrochloride is a small-molecule inhibitor that selectively targets matrix metalloproteinase-13 (MMP-13), also known as collagenase-3. MMP-13 is a zinc-dependent endopeptidase critically involved in the degradation of type II collagen, the principal structural component of articular cartilage. Dysregulated MMP-13 activity is strongly implicated in the pathogenesis of osteoarthritis, rheumatoid arthritis, and other connective tissue diseases.

Unlike classical MMP inhibitors that rely on a hydroxamate zinc-binding group, CL 82198 belongs to a class of non-hydroxamate inhibitors. This structural distinction is significant because hydroxamate-based inhibitors frequently suffer from poor selectivity across MMP family members, leading to off-target effects in experimental settings. CL 82198 demonstrates preferential inhibition of MMP-13 over other MMPs, making it a useful pharmacological tool for dissecting MMP-13-specific contributions to disease biology.

Researchers employ CL 82198 in cell-based and biochemical assays to investigate the role of MMP-13 in extracellular matrix (ECM) degradation, chondrocyte biology, inflammatory signaling, and tissue remodeling. Its selectivity profile supports cleaner mechanistic interpretations compared to pan-MMP inhibitors.

Solution Preparation Protocol

Step 1 – Reconstitution: Allow the vial of CL 82198 hydrochloride (SKU: C287353) to equilibrate to room temperature for at least 15 minutes before opening to minimize moisture condensation. Briefly centrifuge the vial to consolidate any powder that may have settled on the cap or walls.

Step 2 – Solvent selection: CL 82198 hydrochloride is reported to be soluble in DMSO. Prepare a concentrated stock solution (e.g., 10–50 mM) in anhydrous DMSO. Vortex gently and inspect for complete dissolution. If aqueous buffer compatibility is required, dilute the DMSO stock into the appropriate assay buffer to a final DMSO concentration ≤0.1% (v/v) to avoid solvent-related cytotoxicity or enzyme interference. Verify compound solubility at the final working concentration by visual inspection or dynamic light scattering.

Step 3 – Working concentration: Determine the appropriate working concentration empirically for each assay system. Dose–response experiments across a range of concentrations (e.g., 0.1 µM to 100 µM) are recommended to establish IC₅₀ values under your specific assay conditions. Refer to published literature or the Aladdin product datasheet for guidance on reported inhibitory concentrations.

Step 4 – Aliquoting: Prepare single-use aliquots of the stock solution to prevent repeated freeze–thaw cycles, which may compromise compound integrity. Seal aliquots under inert gas (argon or nitrogen) if long-term storage is required.

Note: Always handle DMSO solutions with appropriate PPE (nitrile gloves, safety glasses). DMSO can enhance dermal absorption of co-dissolved materials.

MMP-13 Inhibition Assay Guidance

Biochemical fluorescence assay: MMP-13 inhibitory activity is commonly measured using a fluorogenic substrate cleavage assay. A typical setup involves recombinant active MMP-13 enzyme, a fluorogenic peptide substrate (e.g., a FRET-based peptide selective for collagenase activity), and CL 82198 at varying concentrations. Incubate the enzyme with the inhibitor for an appropriate pre-incubation period (e.g., 15–30 minutes at 37 °C) before adding substrate to allow binding equilibration. Monitor fluorescence at the excitation/emission wavelengths specified for your substrate using a microplate fluorimeter.

Controls: Include a vehicle control (equivalent DMSO concentration), a positive inhibition control (if a reference MMP-13 inhibitor is available), and a no-enzyme blank to correct for substrate background fluorescence. Calculate percent inhibition relative to the uninhibited enzyme control.

Cell-based assays: For cell-based experiments evaluating MMP-13-mediated collagen degradation or chondrocyte responses, add CL 82198 to the culture medium at concentrations determined from biochemical IC₅₀ data. Assess MMP-13 activity in conditioned media by ELISA or zymography. Monitor cell viability in parallel (e.g., MTT or resazurin assay) to distinguish pharmacological effects from cytotoxicity.

Selectivity confirmation: To confirm MMP-13 selectivity in your experimental system, run parallel assays with closely related family members (e.g., MMP-1, MMP-2, MMP-9) under identical conditions. Selectivity data strengthen mechanistic conclusions.

Storage, Stability, and Safety

Storage: Store CL 82198 hydrochloride (C287353) at -20 °C in a tightly sealed container. Protect from light, moisture, and air. Under recommended storage conditions, the compound is expected to be stable for at least 12 months from the date of receipt; verify with the certificate of analysis (CoA) provided with each lot.

Stability considerations: Repeated freeze–thaw cycles should be avoided, as they may lead to compound degradation and reduced biological activity. DMSO stock solutions stored at -20 °C in sealed, low-volume aliquots are generally stable. Aqueous dilutions should be prepared fresh on the day of use.

Safety: CL 82198 hydrochloride is a research-use-only compound. A full Safety Data Sheet (SDS) should be consulted before handling. General laboratory precautions apply: wear nitrile gloves, laboratory coat, and eye protection. Avoid inhalation of dust or aerosols. Dispose of waste according to institutional and local regulations for chemical waste. The compound has not been approved for human or veterinary therapeutic use.

Troubleshooting Common Issues

Poor solubility: If the compound does not dissolve completely in DMSO, warm the vial briefly to 37 °C with gentle vortexing. Do not exceed 60 °C. Sonication in a water bath may assist dissolution. Avoid aqueous solutions without an appropriate co-solvent, as the hydrochloride salt form may have limited aqueous solubility depending on pH and ionic strength.

Weak or no inhibition observed: Verify that the MMP-13 enzyme preparation is active by running a no-inhibitor control and confirming substrate cleavage. Check compound concentration calculations and ensure the stock solution concentration is accurate. Confirm that the pre-incubation time is sufficient for equilibration. Assess whether the assay buffer pH and zinc/calcium ion concentrations are within the range optimal for MMP-13 activity (typically pH 7.0–7.5 with appropriate divalent cations).

High background fluorescence: Reduce substrate concentration or optimize the signal-to-background ratio. Include a no-enzyme blank and subtract background values from all readings. Ensure the compound itself does not fluoresce at the detection wavelengths by measuring compound fluorescence in the absence of enzyme and substrate.

Cytotoxicity in cell assays: If cell viability decreases at the concentrations used, reduce the compound concentration or shorten the exposure time. Confirm that the DMSO vehicle concentration is ≤0.1% (v/v). Evaluate a wider concentration range to identify a therapeutic window with acceptable viability.

Frequently asked questions

What is CL 82198 hydrochloride used for in research?

CL 82198 hydrochloride is used as a selective non-hydroxamate inhibitor of MMP-13 (collagenase-3) in biochemical and cell-based research. It is primarily applied in studies of osteoarthritis, cartilage degradation, and extracellular matrix remodeling to dissect the specific contributions of MMP-13 activity.

What solvent is recommended for dissolving CL 82198 hydrochloride?

CL 82198 hydrochloride is recommended to be dissolved in DMSO to prepare a concentrated stock solution. For aqueous assay conditions, dilute the DMSO stock into the appropriate buffer to achieve a final DMSO concentration of ≤0.1% (v/v) to minimize solvent interference.

How should CL 82198 hydrochloride be stored to maintain stability?

Store CL 82198 hydrochloride at -20 °C in a tightly sealed container, protected from light and moisture. Prepare single-use aliquots of stock solutions to avoid repeated freeze–thaw cycles, and prepare aqueous working solutions fresh on the day of use.

How does CL 82198 differ from hydroxamate-based MMP inhibitors?

Unlike hydroxamate-based MMP inhibitors, which often show broad inhibition across multiple MMP family members, CL 82198 is a non-hydroxamate inhibitor with preferential selectivity for MMP-13. This selectivity makes it a more precise tool for MMP-13-specific research, reducing the risk of off-target effects associated with pan-MMP inhibition.

Can CL 82198 hydrochloride be used in cell-based assays?

Yes, CL 82198 hydrochloride can be used in cell-based assays to evaluate MMP-13-mediated collagen degradation and chondrocyte biology. Researchers should determine appropriate working concentrations empirically and include parallel cell viability assays to distinguish pharmacological effects from cytotoxicity.

References

1. Engel CK et al. Structural basis for the highly selective inhibition of MMP-13. Chemistry & Biology. 2005.
2. Aladdin Scientific. CL 82198 Hydrochloride (C287353) Product Datasheet. Aladdin Scientific.
3. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews Cancer. 2002.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.